Alzheimer's disease (AD) is a neurodegenerative disorder characterised by impairments in
the cognitive domains associated with orientation, recording, and memory. This pathology …

Pharmacogenetics (PGx) is the study and application of how interindividual differences in
our genomes can influence drug responses. By evaluating individuals' genetic variability in …

Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …

Brain derived neurotrophic factor (BDNF) is linked to the pathophysiology of depression. We
hypothesized that BDNF is one of the neurobiological pathways related to the augmentation …

Multiple sclerosis (MS) is a demyelinating, autoimmune disease that affects a large number
of young adults. Novel therapies for MS are needed considering the efficiency and safety …

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous
system (CNS) through neurodegeneration and demyelination, leading to physical/cognitive …

The anatomical changes that antidepressant medications induce in the brain and through
which they exert their therapeutic effects remain largely unknown. We randomized 61 …

This study was designed to investigate the possible antidepressant effects of the antioxidant
alpha-lipoic acid (ALA) as a stand-alone treatment or in association with desvenlafaxine …

Introduction: Early assessment of a therapeutic response is a central goal in antidepressant
treatment. The present study examined the potential for therapeutic drug monitoring and …

Objective Although the safety and efficacy of desvenlafaxine have been demonstrated, long-
term evidence in Asians is lacking. We examined the safety and effectiveness of …